Literature DB >> 31416527

Predicting Major Adverse Events in Patients With Acute Myocardial Infarction.

Thomas Nestelberger1, Jasper Boeddinghaus2, Desiree Wussler3, Raphael Twerenbold4, Patrick Badertscher5, Karin Wildi6, Òscar Miró7, Beatriz López8, F Javier Martin-Sanchez9, Piotr Muzyk10, Luca Koechlin11, Benjamin Baumgartner4, Mario Meier4, Valentina Troester4, Maria Rubini Giménez4, Christian Puelacher3, Jeanne du Fay de Lavallaz4, Joan Walter4, Nikola Kozhuharov4, Tobias Zimmermann4, Danielle M Gualandro4, Eleni Michou4, Eliska Potlukova12, Nicolas Geigy13, Dagmar I Keller14, Tobias Reichlin15, Christian Mueller16.   

Abstract

BACKGROUND: Early and accurate detection of short-term major adverse cardiac events (MACE) in patients with suspected acute myocardial infarction (AMI) is an unmet clinical need.
OBJECTIVES: The goal of this study was to test the hypothesis that adding clinical judgment and electrocardiogram findings to the European Society of Cardiology (ESC) high-sensitivity cardiac troponin (hs-cTn) measurement at presentation and after 1 h (ESC hs-cTn 0/1 h algorithm) would further improve its performance to predict MACE.
METHODS: Patients presenting to an emergency department with suspected AMI were enrolled in a prospective, multicenter diagnostic study. The primary endpoint was MACE, including all-cause death, cardiac arrest, AMI, cardiogenic shock, sustained ventricular arrhythmia, and high-grade atrioventricular block within 30 days including index events. The secondary endpoint was MACE + unstable angina (UA) receiving early (≤24 h) revascularization.
RESULTS: Among 3,123 patients, the ESC hs-cTnT 0/1 h algorithm triaged significantly more patients toward rule-out compared with the extended algorithm (60%; 95% CI: 59% to 62% vs. 45%; 95% CI: 43% to 46%; p < 0.001), while maintaining similar 30-day MACE rates (0.6%; 95% CI: 0.3% to 1.1% vs. 0.4%; 95% CI: 0.1% to 0.9%; p = 0.429), resulting in a similar negative predictive value (99.4%; 95% CI: 98.9% to 99.6% vs. 99.6%; 95% CI: 99.2% to 99.8%; p = 0.097). The ESC hs-cTnT 0/1 h algorithm ruled-in fewer patients (16%; 95% CI: 14.9% to 17.5% vs. 26%; 95% CI: 24.2% to 27.2%; p < 0.001) compared with the extended algorithm, albeit with a higher positive predictive value (76.6%; 95% CI: 72.8% to 80.1% vs. 59%; 95% CI: 55.5% to 62.3%; p < 0.001). For 30-day MACE + UA, the ESC hs-cTnT 0/1 h algorithm had a higher positive predictive value for rule-in, whereas the extended algorithm had a higher negative predictive value for the rule-out. Similar findings emerged when using hs-cTnI.
CONCLUSIONS: The ESC hs-cTn 0/1 h algorithm better balanced efficacy and safety in the prediction of MACE, whereas the extended algorithm is the preferred option for the rule-out of 30-day MACE + UA. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE]; NCT00470587).
Copyright © 2019 American College of Cardiology Foundation. All rights reserved.

Entities:  

Keywords:  acute myocardial infarction; clinical assessment; electrocardiography; high-sensitivity cardiac troponin; major adverse cardiac events

Mesh:

Substances:

Year:  2019        PMID: 31416527     DOI: 10.1016/j.jacc.2019.06.025

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Finding acute coronary syndrome with serial troponin testing for rapid assessment of cardiac ischemic symptoms (FAST-TRAC): a study protocol.

Authors:  W Frank Peacock; Alan S Maisel; Christian Mueller; Stefan D Anker; Fred S Apple; Robert H Christenson; Paul Collinson; Lori B Daniels; Deborah B Diercks; Salvatore Di Somma; Gerasimos Filippatos; Gary Headden; Brian Hiestand; Judd E Hollander; Juan C Kaski; Joshua M Kosowsky; John T Nagurney; Richard M Nowak; Donald Schreiber; Gary M Vilke; Marvin A Wayne; Martin Than
Journal:  Clin Exp Emerg Med       Date:  2022-06-30

2.  The Diagnostic Value of Serum GDF15 and hs-CTnT in Elderly Patients with Acute Myocardial Infarction.

Authors:  Yejun He; Hui Wang; Zhihua Fang
Journal:  Comput Intell Neurosci       Date:  2022-05-20

3.  The Long Noncoding RNA Hotair Regulates Oxidative Stress and Cardiac Myocyte Apoptosis during Ischemia-Reperfusion Injury.

Authors:  Kai Meng; Jiao Jiao; Rui-Rui Zhu; Bo-Yuan Wang; Xiao-Bo Mao; Yu-Cheng Zhong; Zheng-Feng Zhu; Kun-Wu Yu; Yan Ding; Wen-Bin Xu; Jian Yu; Qiu-Tang Zeng; Yu-Dong Peng
Journal:  Oxid Med Cell Longev       Date:  2020-03-12       Impact factor: 6.543

4.  Association of Previous Myocardial Infarction and Time to Presentation With Suspected Acute Myocardial Infarction.

Authors:  Valentina Troester; Ivo Strebel; Thomas Nestelberger; Jasper Boeddinghaus; Maria Rubini Gimenez; Pedro Lopez-Ayala; Luca Koechlin; Noemi Glarner; Alexandra Prepoudis; Òscar Miró; F Javier Martin-Sanchez; Damian Kawecki; Dagmar I Keller; Raphael Twerenbold; Christian Mueller
Journal:  J Am Heart Assoc       Date:  2020-12-26       Impact factor: 5.501

5.  Diagnostic Value of Circulating Progranulin and Its Receptor EphA2 in Predicting the Atheroma Burden in Patients with Coronary Artery Disease.

Authors:  Dan Tian; Qing Qin; Ruiyan Liu; Zi Wang; Xiaoyu Li; Qing Xu; Qianzhou Lv
Journal:  Dis Markers       Date:  2021-04-21       Impact factor: 3.434

6.  Implementation of an early rule-out pathway for myocardial infarction using a high-sensitivity cardiac troponin T assay.

Authors:  Dennis Sandeman; Maaz B J Syed; Dorien M Kimenai; Kuan Ken Lee; Atul Anand; Shruti S Joshi; Lorraine Dinnel; Philip R Wenham; Ken Campbell; Mary Jarvie; Donna Galloway; Mhairi Anderson; Bappa Roy; Jack P M Andrews; Fiona E Strachan; Amy V Ferry; Andrew R Chapman; Sarah Elsby; Mark Francis; Robert Cargill; Anoop S V Shah; Nicholas L Mills
Journal:  Open Heart       Date:  2021-11

7.  Baseline High Sensitivity Cardiac Troponin I Level Below Limit of Quantitation Rules Out Acute Myocardial Infarction in the Emergency Department.

Authors:  Bernard Cook; James McCord; Michael Hudson; Waleed Al-Darzi; Michele Moyer; Gordon Jacobsen; Richard Nowak
Journal:  Crit Pathw Cardiol       Date:  2021-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.